PRECISE-DAPT Score

Intended Population

• Use the PRECISE-DAPT Score at the time of PCI or hospital discharge to estimate a patient’s bleeding risk during dual antiplatelet therapy (DAPT). 

• It helps determine whether a shorter (3–6 month) versus standard or longer (≥12 month) DAPT duration is more appropriate based on bleeding risk.

• Applicable to patients receiving aspirin plus a P2Y12 inhibitor and not on oral anticoagulation.

PRECISE-DAPT Score

The PRECISE-DAPT score is a validated clinical prediction tool that estimates the 1-year risk of out-of-hospital bleeding in patients treated with dual antiplatelet therapy (DAPT) after coronary stent implantation. It helps guide a key clinical decision: whether a patient should receive a standard/prolonged DAPT course (12–24 months) or a shortened one (3–6 months).

Development

The score was derived by Costa, Valgimigli, and colleagues (2017) from a pooled analysis of 14,963 patients across eight multicenter randomized clinical trials, treated with DAPT (mostly aspirin plus clopidogrel) after PCI with coronary stent implantation. Patients requiring long-term oral anticoagulation were excluded. It was externally validated in two independent cohorts: the PLATO trial (n=8,595) and the BernPCI registry (n=6,172).

The primary outcome was out-of-hospital TIMI major or minor bleeding, defined as bleeding occurring 7 or more days after the procedure (to exclude procedure-related in-hospital bleeding).

How the Points Are Calculated

The five components are scored individually (each anchored at 0 for the "best" value) and summed into a single integer between 0 and 100:

Each variable scales roughly linearly between its floor and ceiling. Points sum to a maximum of 100 across all five factors, matching the published statement that scores range from 0–100 — previous bleeding is the single heaviest-weighted factor, contributing more than a quarter of the total possible score on its own. Refer to the EVAL builder feature to view formulas.

Translating Score to Bleeding Risk

The nomogram also plots two risk curves — 12-month TIMI major-or-minor bleeding and TIMI major bleeding alone — as roughly exponential functions of the total score. Some published reference points:

Risk Categories

The score was validated using population quartiles from the derivation cohort:

A score of 25 or higher is the key clinical threshold: this identifies patients for whom prolonged DAPT provides no net ischemic benefit but meaningfully increases bleeding risk (number needed to harm: 38). Patients below 25 tend to benefit from standard or extended DAPT without excessive bleeding liability.

Result Notations

• For a score <25, a standard DAPT duration can be considered (12 months or according to the ischemic risk profile). A longer duration gives ischemic benefit in this group without appreciable excess bleeding.

• For a score >24 , consider short DAPT (3–6 months) if ischemic risk is low or bleeding risk is a concern, then transition to single antiplatelet therapy. In the derivation cohort, longer DAPT significantly increased bleeding risk in this group without a corresponding ischemic benefit.

• The score not only ranks bleeding risk but identifies patients in whom long DPAT duration may carry net harm. The study analysis demonstrated that longer treatment (12-24 months) significantly increased bleeding in patients with a score >24, but not in those with a lower score. Additionally, the ischemic benefit of extended treatment was only seen in the low-score group (Costa, 2017).

Result Considerations

• Always individualize duration based on bleeding vs. ischemic risk, stent type, and presentation—some lower-bleeding-risk patients may still benefit from longer DAPT.

• Closely monitor renal function, hemoglobin and clinical status for any changes that may impact treatment strategy.

• Clinical judgement and best practice (e.g. current cardiology guidelines) supersedes adjunct standalone decision tools.

• Risk and benefits of between bleeding and ischemic risk should be considered in patients, to include shared decision-making and informed consent, prior to initiating therapy. 

• Address modifiable risk factors for bleeding (e.g., treat anemia, discontinue unnecessary antithrombotics).

Performance

The score showed a c-index of 0.73 for TIMI major/minor bleeding in the derivation cohort, with 0.70 and 0.66 in the two external validation cohorts — moderate-to-good discrimination, and it outperformed the comparator PARIS bleeding score on integrated discrimination and reclassification metrics in both validation cohorts.

Guideline Standing and Practical Use

PRECISE-DAPT carries a Class IIb, Level of Evidence A recommendation in the 2017 ESC Focused Update on DAPT for informing treatment-duration decisions. A simplified four-item version (dropping WBC count) has also been validated with only minimal loss of predictive accuracy, useful when WBC isn't readily available. It's often used alongside the ischemia-focused DAPT score — a low PRECISE-DAPT score (<25) paired with a DAPT score ≥2 supports prolonging therapy, while a high PRECISE-DAPT score generally favors shortening it regardless of ischemic risk.

Practical note: As with the other risk scores we've covered, PRECISE-DAPT is meant to inform — not replace — individualized clinical judgment or clinical practice guidelines, particularly given it was derived from a population largely on clopidogrel (88%) rather than the more potent P2Y12 inhibitors now in wider use.

Clinical Practice Guidelines

1. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal, Volume 39, Issue 3, 14 January 2018, Pages 213–260.

2. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826.

3. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119.

4. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025 Apr;151(13):e771-e862. doi: 10.1161/CIR.0000000000001309. Epub 2025 Feb 27. Erratum in: Circulation. 2025 Apr;151(13):e865.

Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017 Mar 11;389(10073):1025-1034.